Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a research report on Friday, March 7th.

Evogene Stock Performance

Shares of NASDAQ:EVGN opened at $1.15 on Friday. The firm has a market capitalization of $6.17 million, a PE ratio of -0.26 and a beta of 1.37. The firm has a fifty day moving average of $1.26 and a 200 day moving average of $1.58. Evogene has a 52-week low of $0.95 and a 52-week high of $9.00.

Evogene (NASDAQ:EVGN) last issued its earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The company had revenue of $1.61 million during the quarter, compared to analysts’ expectations of $3.63 million. During the same period in the prior year, the business posted ($1.30) EPS.

Hedge Funds Weigh In On Evogene

A hedge fund recently bought a new stake in Evogene stock. Citadel Advisors LLC acquired a new position in Evogene Ltd. (NASDAQ:EVGN) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned about 0.30% of Evogene as of its most recent filing with the SEC. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.